The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.50
Bid: 42.00
Ask: 45.00
Change: 0.00 (0.00%)
Spread: 3.00 (7.143%)
Open: 43.50
High: 43.50
Low: 43.50
Prev. Close: 43.50
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights and Director/PDMR Shareholding

21 Nov 2018 11:00

RNS Number : 0841I
Frontier IP Group plc
21 November 2018
 

21 November 2018

 

Frontier IP Group plc

("Frontier IP" or the "Company")

 

Total Voting Rights and Director/PDMR Shareholdings

 

Frontier IP, which specialises in commercialising university intellectual property, announces that the 3,827,852 new ordinary shares of 10 pence each in the Company ("Ordinary Shares") issued pursuant to the placing announced on 15 November 2018 (the "Placing") have today been admitted to trading on AIM ("Admission") and the Placing has completed. The Company's issued share capital now consists of 42,106,372 Ordinary Shares with one voting right each. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company is 42,106,372.

 

This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Director/PDMR Shareholdings

 

Michael Bourne, Non-Executive Director of the Company, subscribed for 32,932 Ordinary Shares in the Placing at a price of 65 pence per share and now holds a total interest in 303,170 Ordinary Shares, equivalent to 0.72 per cent. of the Company's enlarged ordinary share capital. Details of this purchase were included in the announcement on 15 November 2018.

 

Following Admission, the Directors' beneficial shareholdings are as follows:

 

 

Director

Interest in Ordinary Shares upon Admission

Percentage of voting rights in the Company upon Admission

Andrew Richmond (Non-executive Chairman)

1,000,000

2.37

Neil Crabb (Chief Executive Officer)

2,834,168

6.73

James Fish (Finance Director)

100,000

0.23

Jacqueline McKay (Chief Operating Officer)

12,855

0.03

David Cairns (Portfolio Director)

840,238

1.99

Michael Bourne (Non-executive Director)

303,170

0.72

Campbell Wilson (Non-executive Director)

-

-

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Bourne

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Frontier IP Group plc

b)

LEI

213800BRYUKQPJWKJ312

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 10p each in Frontier IP Group Plc

 

Identification code (ISIN) for Frontier IP Group Plc ordinary shares: GB00B63PS212

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

65.00p

32,932

 

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transactions

21 November 2018

f)

Place of the transaction

Outside a Trading Venue - placing of new ordinary shares

 

The information set out in this announcement is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

Enquiries:

Frontier IP Group plc

T: 0131 240 1251

Neil Crabb, Chief Executive

 

Andrew Johnson, Communications & Investor Relations

M: 07464 546 025

www.frontierip.co.uk

 

 

 

Allenby Capital Limited (Nominated Adviser and Broker)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers (Corporate Finance)

 

Amrit Nahal (Equity Sales)

 

Notes to Editors:

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. The group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKMMZMGMDGRZM
Date   Source Headline
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.